Hypertension As with other angiotensin II receptor antagonists,<unk>  is indicated for the treatment of hypertension.<unk>  has an additive antihypertensive effect when combined with a diuretic, such as chlorthalidone. It is available in a fixed-combination formulation with a low dose of the thiazide diuretic hydrochlorothiazide.<unk> /hydrochlorothiazide combination preparations are marketed under various trade names including Atacand Plus, Hytacand, Blopress Plus, Advantec and Ratacand Plus. Congestive heart failure Angiotensin receptor blockers such as<unk>  and valsartan have been demonstrated in randomised controlled trials to reduce heart failure hospitalisations and cardiovascular deaths for chronic heart failure patients with reduced left ventricular ejection fraction (LVEF ≤40%) and are intolerant to angiotensin-converting enzyme inhibitors. Prehypertension In a four-year randomized controlled trial,<unk>  was compared to placebo to see whether it could prevent or postpone the development of full-blown hypertension in people with so-called prehypertension. During the first two years of the trial, half of participants were given<unk>  while the other half received placebo;<unk>  reduced the risk of developing hypertension by nearly two-thirds during this period. In the last two years of the study, all participants were switched to placebo. By the end of the study,<unk>  had significantly reduced the risk of hypertension, by more than 15%. Serious adverse effects were more common among participants receiving placebo than in those given<unk> . Prevention of atrial fibrillation Results from a meta-analysis completed in 2005 demonstrated a reduction in atrial fibrillation in patients with systolic left ventricular dysfunction treated with<unk> , another angiotensin receptor blocker or an angiotensin converting enzyme inhibitor. Evidence for the use of<unk>  specifically is also supported by an analysis of the CHARM study which demonstrated a reduction in atrial fibrillation in patients with systolic left ventricular dysfunction. While these studies have demonstrated a potential additional benefit for<unk>  when used in patients with systolic left ventricular dysfunction, additional studies are required to further elucidate the role of<unk>  in the prevention of atrial fibrillation in other population groups. Diabetic retinopathy Use of antihypertensive drugs has been demonstrated to slow the progression of diabetic retinopathy; the role of<unk>  specifically in reducing progression in type 1 and type 2 diabetes is still up for debate. Results from a 2008 study on patients with type 1 diabetes showed there was no benefit in using<unk>  to reduce progression of diabetic retinopathy when compared to placebo.<unk>  has been demonstrated to reverse the severity (cause regression) of mild to moderate diabetic retinopathy in patients with type 2 diabetes. The patient populations investigated in these studies were limited to mostly Caucasians and those younger than 75 years of age, so generalization of these findings to other population groups should be done with caution. Migraine prophylaxis In two small randomised, controlled cross-over studies,<unk>  was shown to be effective for the prophylaxis of migraine, however, further studies would enhance confidence in its use for this indication.
Candesartan
Olmesartan
Irbesartan
Valsartan
Losartan
Azilsartan
Cyclothiazide
Telmisartan